Advocacy Relations

The concurrent effects of the novel coronavirus and sweeping demands for racial equity are, arguably, creating the greatest social disruption America has witnessed in the last 50 years. While the [...]

At JPA, we believe in collaboration between patient organizations and pharmaceutical companies. So much so, that we have an entire team dedicated to patient advocacy relations. In almost all [...]

The FDA Office of New Drugs held a public meeting earlier this month to invite discussions and policy suggestions that promote effective drug development programs. Considering the unprecedented [...]

Early this year, two papers published in JAMA and BMJ reported on inconsistent financial disclosure practices among non-profit patient advocacy organizations and drug manufacturers. This is the [...]

On October 12, World Sight Day, a Food and Drug Administration (FDA) advisory committee voted unanimously 16-0 in favor of recommending the approval of Luxturna, a gene therapy developed by Spark [...]

With the authorization of $1.8 billion in funding for the Cancer Moonshot over 7 years, we’ve seen both hope and hype around how we accelerate cancer research to make more treatments available to [...]

The passing of the 21st Century Cures Act (Cures) carries with it a prominent focus on the involvement of patients in every stage of the pharmaceutical development process. In some respects, this [...]

Last week, I had the opportunity to attend MassBio & Sanofi Genzyme’s event entitled “No Borders: A Conversation on Global Humanitarian Programs.” The overarching theme resided in the notion [...]

The 8th Parliamentary term of the European Parliament offers a fresh opportunity for patient groups and industry bodies to align with policymakers with an interest in driving better health [...]

This summer, the eyes of the global HIV community were turned on Melbourne and the 20th International Aids Conference. The Conference was a combination of the latest breakthroughs in science and [...]